Noven
Pharmaceuticals, Inc. is a specialty pharmaceutical
company engaged in the research, development, manufacture, marketing
and sale of prescription pharmaceutical products. Noven has over 650
employees working in facilities located in: Miami, FL; New York, NY;
Carlsbad, CA; and Florham Park, NJ, and in sales force territories
located across the U.S. Noven is an indirect wholly-owned subsidiary
of Hisamitsu Pharmaceutical Co., Inc., and Noven serves as Hisamitsu's
growth platform in the U.S. Noven’s
business and operations are focused in three principal areas – transdermal
drug development and manufacturing, the Novogyne joint venture with
Novartis Pharmaceuticals Corporation, and Noven Therapeutics, Noven’s
specialty pharmaceutical unit.
Noven’s commercialized
transdermal products include Vivelle-Dot® (estradiol
transdermal system), the most prescribed estrogen patch in the U.S.,
and Daytrana® (methylphenidate transdermal system), the
first and only patch approved for the treatment of ADHD. Both patches
utilize Noven’s proprietary DOT Matrix® transdermal
delivery technology. Noven’s commercialized oral products, marketed
and sold by Noven Therapeutics, consist of Stavzor® (delayed release
valproic acid softgel), Pexeva® (paroxetine mesylate)
and Lithobid® (lithium
carbonate).